PRAX has shown dramatic gains, with shares up hundreds of percent over the past year, driven by positive clinical data and strong biotech sentiment.

Analysts have been raising price targets, with some forecasts significantly above current levels — including targets as high as the $750+ and even $843 range from bullish analysts.

The average analyst 12-month price target sits well above the current price, indicating an upside bias from Wall Street consensus.

#USJobsData #BTC100kNext? #CPIWatch #GoldSilverAtRecordHighs